The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Sandoz; Seagen
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Bristol-Myers Squibb (I); Frensenius Medical Care; G1 Therapeutics
Research Funding - Amgen
 
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Janssen; MSD Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; MSD Oncology; Novartis; Pfizer
Research Funding - Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; MSD Oncology
The evolving value assessment of cancer therapies: Principles from the cancer community.
 
Myrto Lee
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo Pharmaceutical (Inst); Galapagos NV (Inst); Pfizer (Inst); SOBI (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Daiichi Sankyo Pharmaceutical (Inst); Galapagos NV (Inst); Pfizer (Inst); SOBI (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Daiichi Sankyo Pharmaceutical (Inst); Galapagos NV (Inst); Pfizer (Inst); SOBI (Inst)
 
Anne-Marie Baird
Honoraria - AstraZeneca; Roche
Other Relationship - Lung Cancer Europe
(OPTIONAL) Uncompensated Relationships - Roche
 
Susan Brown
Stock and Other Ownership Interests - Merck
 
Russell Clark
Employment - Cancer Technology Applications, LLC
Leadership - Cancer Technology Applications (CTA)
Stock and Other Ownership Interests - CTA
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Foundation Medicine; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Daichii Sankyo; Pfizer; Roche/Genentech
 
Andrea Stern Ferris
Stock and Other Ownership Interests - JNJ
Travel, Accommodations, Expenses - Amgen
 
Ataru Igarashi
Honoraria - ABBVIE/ABBOTT; GlaxoSmithKline K.K.; Novartis; Novo Nordisk; Pfizer
Consulting or Advisory Role - argenx; Asahi Kasei; GlaxoSmithKline K.K.; Janssen; Lilly Japan; Novartis; Novo Nordisk; Ono Pharmaceutical; Pfizer; Takeda
Speakers' Bureau - Chugai Pharma; Moderna Therapeutics; MSD K.K
Research Funding - Becton Dickinson; Edwards Lifesciences; Eisai; Intuitive Japan; Janssen; Milliman; Taiho Pharmaceutical; Takeda; Varian Medical Systems
 
Ravindran Kanesvaran
No Relationships to Disclose
 
Hugo Larose
Consulting or Advisory Role - AstraZeneca (Inst)
 
Gary Lyman
No Relationships to Disclose
 
Luca Pani
Leadership - EDRA; NetraMark; Relmada Therapeutics
Stock and Other Ownership Interests - NetraMark; Relmada Therapeutics
Consulting or Advisory Role - Abbvie; Acadia Pharmaceuticals; Boehringer Ingelheim; Boston Consulting Group; Compass Pathways Inc.; ImmunoGen; Inpeco; Johnson & Johnson; Novartis; Nurosene; Pfizer; PharmaMar; Relmada Therapeutics; Sanofi; Takeda; Vifor Pharma; WCG
Travel, Accommodations, Expenses - EDRA
 
Zack Pemberton-Whiteley
Honoraria - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Gilead Sciences (Inst); Janssen (Inst); Janssen (Inst); Novartis (Inst); Takeda (Inst)
Research Funding - AbbVie (Inst); Adaptive Biotechnologies (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Autolus (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Glycostem (Inst); Incyte (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Kyowa Kirin International (Inst); Kyowa Kirin International (Inst); Lilly (Inst); Mallinckrodt (Inst); Novartis (Inst); Pfizer (Inst); Pleco Therapeutics (Inst); SERVIER (Inst); Takeda (Inst)
 
Tomas Salmonson
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca
 
Peter Sawicki
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
 
Barry D. Stein
Honoraria - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Dong-Churl Suh
No Relationships to Disclose
 
Galina Velikova
Honoraria - Eisai; Roche UK; Sanofi; Seagen
Consulting or Advisory Role - Eisai; Novartis; Roche UK; Sanofi
Speakers' Bureau - Novartis
Research Funding - IQVIA (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Roche UK
Other Relationship - University of Leeds
 
Richard Vines
Honoraria - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Jens Grueger
Employment - Roche (I)
Stock and Other Ownership Interests - Roche
Consulting or Advisory Role - Apellis Pharmaceuticals; AstraZeneca; Gilead Sciences; GlaxoSmithKline; Highlight Therapeutics; Johnson & Johnson; Neurocrine Biosciences; Otsuka; Regeneron; Sanofi